193 related articles for article (PubMed ID: 15238984)
1. A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
Harries M; Moss C; Perren T; Gore M; Hall G; Everard M; A'Hern R; Gibbens I; Jenkins A; Shah R; Cole C; Pizzada O; Kaye S
Br J Cancer; 2004 Aug; 91(4):627-32. PubMed ID: 15238984
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Micha JP; Goldstein BH; Rettenmaier MA; Mattison J; Graham C; Birk CL; Brown JV
Gynecol Oncol; 2004 Sep; 94(3):719-24. PubMed ID: 15350364
[TBL] [Abstract][Full Text] [Related]
3. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Hook J; Coyle C; Blagden S; Brenton JD; Naik R; Perren T; Sundar S; Cook AD; Gopalakrishnan GS; Gabra H; Lord R; Dark G; Earl HM; Hall M; Banerjee S; Glasspool RM; Jones R; Williams S; Swart AM; Stenning S; Parmar M; Kaplan R; Ledermann JA
Lancet; 2019 Dec; 394(10214):2084-2095. PubMed ID: 31791688
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
5. SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
Vasey PA; Atkinson R; Osborne R; Parkin D; Symonds R; Paul J; Lewsley L; Coleman R; Reed NS; Kaye S; Rustin GJ
Br J Cancer; 2006 Jan; 94(1):62-8. PubMed ID: 16404361
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Gordon AN; Teneriello M; Janicek MF; Hines J; Lim PC; Chen MD; Vaccarello L; Homesley HD; McMeekin S; Burkholder TL; Wang Y; Zhao L; Orlando M; Obasaju CK; Gill JF; Tai DF
Gynecol Oncol; 2011 Dec; 123(3):479-85. PubMed ID: 21978765
[TBL] [Abstract][Full Text] [Related]
7. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
8. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
10. Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
Mäenpää JU; Grénman SE; Jalkanen JT; Kuoppala TA; Leminen AO; Puistola US; Vuolo-Merilä PM; Yliskoski MH
Gynecol Oncol; 2006 Apr; 101(1):114-9. PubMed ID: 16266743
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
Konner J; Schilder RJ; DeRosa FA; Gerst SR; Tew WP; Sabbatini PJ; Hensley ML; Spriggs DR; Aghajanian CA
Gynecol Oncol; 2008 Aug; 110(2):140-5. PubMed ID: 18554700
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer.
Friedlander M; Buck M; Wyld D; Findlay M; Fitzharris B; De Souza P; Davies T; Kalimi G; Allan S; Perez D; Harnett P
Int J Gynecol Cancer; 2007; 17(2):350-8. PubMed ID: 17362312
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.
Hensley ML; Correa DD; Thaler H; Wilton A; Venkatraman E; Sabbatini P; Chi DS; Dupont J; Spriggs D; Aghajanian C
Gynecol Oncol; 2006 Aug; 102(2):270-7. PubMed ID: 16490239
[TBL] [Abstract][Full Text] [Related]
14. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
[TBL] [Abstract][Full Text] [Related]
15. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
[TBL] [Abstract][Full Text] [Related]
16. SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
Clamp AR; Mäenpää J; Cruickshank D; Ledermann J; Wilkinson PM; Welch R; Chan S; Vasey P; Sorbe B; Hindley A; Jayson GC;
Br J Cancer; 2006 Jan; 94(1):55-61. PubMed ID: 16404360
[TBL] [Abstract][Full Text] [Related]
17. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Look KY; Bookman MA; Schol J; Herzog TJ; Rocereto T; Vinters J;
Gynecol Oncol; 2004 Jan; 92(1):93-100. PubMed ID: 14751144
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
Tiersten AD; Sill MW; Knight D; Muggia F; Garcia AA; Swensen R; Warshal DP; Mannel RS; Fracasso PM
Gynecol Oncol; 2010 Sep; 118(3):303-7. PubMed ID: 20547415
[TBL] [Abstract][Full Text] [Related]
19. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial.
Markman M; Glass T; Smith HO; Hatch KD; Weiss GR; Taylor SA; Goodwin JW; Alberts DS
Gynecol Oncol; 2003 Mar; 88(3):282-8. PubMed ID: 12648576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
